Clinical Trials on Vitamine c in New Zealand

Total 582 results

SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
NYU Langone Health

Completed

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

Hepatitis C

United States
Beth Israel Deaconess Medical Center

Completed

Thiamine as a Renal Protective Agent in Septic Shock

Sepsis | Kidney Injury | Thiamine Deficiency

United States
Kirby Institute
Justice Health & Forensic Mental Health Network NSW Australia

Completed

Prisons Evaluation of a One-stop-shop InterVentiOn (PIVOT)

Hepatitis C

Australia
Icahn School of Medicine at Mount Sinai
KineMed

Terminated

Biomarkers of Liver Fibrosis

Hepatitis C

United States
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Proteus Digital Health, Inc.

Unknown

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (DASH)

Hepatitis C, Chronic | Nonadherence, Patient

United States
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection (ASTRAL-1)

Hepatitis C Virus Infection

United States, France, Canada, Germany, Puerto Rico, United Kingdom, Belgium, Italy, China
Gilead Sciences

Completed

Phase 3 Study of Sofosbuvir and Ribavirin (FISSION)

Hepatitis C

United States, Australia, Canada, Puerto Rico, New Zealand, Sweden, Italy, Netherlands
Icahn School of Medicine at Mount Sinai

Completed

Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood

Hepatitis C | HCV | Liver Transplant

United States
City University of New York, School of Public Health
National Institute on Drug Abuse (NIDA); Weill Medical College of Cornell University and other collaborators

Completed

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

Hepatitis C | HCV Coinfection | People Who Inject Drugs | PWID

United States
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Mesoblast, Inc.
Quintiles, Inc.

Completed

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Grade B aGVHD | Grade C aGVHD | Grade D aGVHD

United States
Prisma Health-Upstate
Johns Hopkins University; Massachusetts General Hospital; Montefiore Medical... and other collaborators

Completed

Patient-Centered Models of HCV Care for People Who Inject Drugs (HERO)

Hepatitis C | Medication Adherence

United States
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Completed

Effects of HIV and Hepatitis C Virus on the Brain

HIV Infections | Hepatitis C

United States
Albert Einstein College of Medicine
Merck Sharp & Dohme LLC; AiCure

Completed

Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs

Hepatitis C | Medication Adherence

United States
AbbVie

Completed

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, France, Germany, Poland, Puerto Rico, Russian Federation, Spain, United Kingdom
Gilead Sciences

Completed

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Hepatitis C Virus Infection

United States, Belgium, Italy, United Kingdom
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Completed

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection

Hepatitis C | HIV | Co-Infection

United States
Actelion

Completed

Miglustat in Niemann-Pick Type C Disease

Niemann-Pick Type C Disease

United States
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

Hepatitis C, Chronic

United States
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Hepatitis C, Chronic

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Hepatitis C Virus

France, Spain, United Kingdom, United States, Germany, Italy, Argentina, Ireland
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Hepatitis C, Chronic

United States, Puerto Rico
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
State University of New York at Buffalo

Completed

Hepatitis C-Video vs. Brochure Education Delivery

Hepatitis C

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Hepatitis C | HIV-1 Infection

United States
James J. Peters Veterans Affairs Medical Center

Completed

Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI

Vitamin D Deficiency | Spinal Cord Injury

United States
SC Liver Research Consortium, LLC
Janssen, LP

Completed

SMV + SOF With/Without RBV for IFN-II Patients With CHC

Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Henry Sacks
National Institute of Nursing Research (NINR)

Completed

A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

HIV Infections | Hepatitis C

United States
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Albert Einstein College of Medicine
National Institute on Drug Abuse (NIDA)

Completed

Directly Observed Hepatitis C Treatment in Methadone Clinics

Hepatitis C | Medication Adherence

United States
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Yale University

Terminated

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study (HERCULES)

Hepatitis C | Liver Transplant; Complications

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Canada, Australia, Israel, Germany, Czech Republic, France, Poland, Romania
Weill Medical College of Cornell University

Completed

Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Obesity | Vitamin D Deficiency | Secondary Hyperparathyroidism

United States
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Hoffmann-La Roche

Completed

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Sweden, United States, Romania, United Kingdom, Denmark, Germany, Russian Federation, Canada, Puerto Rico, Hungary, Poland, Netherlands, Brazil
Kirby Institute

Completed

Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C)

Hepatitis C

Australia
MassBiologics

Terminated

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C (MBL-HCV1)

Liver Transplantation | HCV Infection

United States
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
National Institute on Drug Abuse (NIDA)

Completed

Study to Reduce Intravenous Exposures (STRIVE)

HIV Infections | Hepatitis C

United States

Clinical Trials on Vitamine c in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations